Biotricity Inc. (“Biotricity”) today announced its financial results for the third quarter of fiscal 2025 year and (unaudited) ended December 31, 2024.  Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, “In the third quarter of fiscal 2025, we continued our mission to innovate and develop transformative healthcare technologies, while demonstrating our strong commitment to automation, operating efficiency and financial discipline. Our primary focus remains on driving revenue and margins and as such, we were pleased to see these metrics trend upwards. This quarter we continued to leverage our data intelligently, pushing the boundaries of what’s possible in healthcare outcomes through cutting-edge research and development. This dedication has allowed us to redefine medical diagnostics and patient care by introducing innovative AI-driven solutions”.

Biotricity Inc. (“Biotricity”) and B-Secur, a leader in biosensing technology, have joined forces to create one of the most advanced, device-neutral platforms for integrated heart monitoring.  By combining B-Secur’s HeartKey^® technology, a suite of FDA-cleared algorithms and analytics, with Biotricity’s medical and consumer diagnostic solutions, the new partnership will empower Integrated Delivery Networks, healthcare providers, health systems, and Independent Diagnostic Testing Facilities with enhanced capabilities for Ambulatory Cardiac Monitoring and ambulatory devices.